MA5-12808

antibody from Invitrogen Antibodies

Targeting: MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau

Provider product page for MA5-12808

Western blot

Immunocytochemistry

Immunoprecipitation

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [92]
Comments [0]
Validations
Immunocytochemistry [1]
Other assay [9]

Submit

Product number: MA5-12808 - Provider product page
Provider: Invitrogen Antibodies
Product name: Tau Monoclonal Antibody (TAU-5)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA5-12808 targets TAU in immunofluorescence, immunoprecipitation, and Western blot applications and shows reactivity with Bovine, Human, mouse, Ovine, and Rat samples. The MA5-12808 immunogen is purified bovine microtubule-associated proteins.
Reactivity: Human, Mouse, Rat, Bovine
Host: Mouse
Isotype: IgG
Antibody clone number: TAU-5
Vial size: 500 µL
Concentration: 0.2 mg/mL
Storage: 4° C

MAPT protein structure - MA5-12808 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of TAU using TAU Monoclonal Antibody (Product # MA5-12808) on denatured Human IMR-5 Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Confocal microscopy analysis of untransfected human fibroblasts. Cells isolated from a skin biopsy showed a positive reactivity for Tau5 (cytoplasm), PHF (nucleus), and AT8 anti-serum (cytoplasm and nucleus). Nuclei were stained with Sytox (in red), while Tau was detected through FITC conjugated to the secondary antibody (in green). Sytox/FITC signal overlap is observed in yellow.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Assessment of Tau overexpression by Western blot. Total protein extracts from fibroblasts under distinct experimental conditions were subjected to immunodetection using Tau5 antibody. beta-actin immunodetection was performed as loading control. UnFs, untransfected fibroblasts; TFs, fibroblasts transfected with pVAX-Tau.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Effect of ICA on the phosphorylation level of Tau in NaN 3 -injured PC12 cells. (A) Representative bands showing PHF-1 and p-T217 in PC12 cells in the different groups. (B) Quantitative analysis of PHF-1 levels. (C) Quantitative analysis of p-T217 levels. Phosphorylated Tau was normalized to total Tau. The data are shown as the mean +- SEM, n = 5 (* P < 0.05 vs. the control group, # P < 0.05 vs. the NaN 3 group).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Curcumin treatment prevents apoptotic and MAPK pathways activation in ex vivo model of retinal degeneration. A Representative western blots and relative quantifications showed the reduction of Caspase-9, cleaved-Caspases-3, BCL2, and BAX levels in retina homogenates caused by the 24 h pre-treatment of curcumin (5 and 10 muM) if compared to induced retinal degeneration at time 24. The BCL-XL level was significantly increased by 5 muM of curcumin administration. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 [ n = 5]. Data were expressed as mean +- SEM. One-way ANOVA, Tukey's post hoc test. B , C Representative western blots and relative quantifications of JNK, c-Jun, ERK, and Tau. B Graphs indicated a significant augmented p-JNK/JNK and p-c-Jun/C-Jun ratios at time 24, reduced by curcumin administration; 5 muM of curcumin significantly increase p-JNK/JNK ratio if compared to other experimental conditions. C A significant decrease of p-ERK/ERK ratio at time 24 was caused by 5 and 10 muM of curcumin administration. The augmented p-Tau/Tau ratio observed at time 24 was reduced by curcumin treatment. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 [ n = 5]. Data were expressed as mean +- SEM. One-way ANOVA, Tukey's post hoc test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. Tau Associates and Genetically Interacts with Spliceosomal Factors (A) Following coimmunoprecipitation, 1,065 Tau-associated proteins were identified from AD or control postmortem brain tissue homogenates (n = 4 each). Volcano plot highlights proteins showing >1.5-fold increased (red) or decreased (green) interactions with Tau in AD (all p < 0.05), including numerous ribonucleoproteins (p = 7.7 x 10 -5 ). Spliceosome components are denoted. See also Figure S1 , Tables S1 , and Data S1 , tabs i and ii. (B) Compared with controls (Ctrl, top left), Tau V337M expression in the eye ( GMR-GAL4 ) causes reduced eye size and roughened surface (bottom left: 1.98 +- 0.08, mean score +- SEM, n > 35 for all genotypes), and RNAi targeting spliceosome factors enhanced toxicity (bottom row, p < 0.0001: SmB , 3.67 +- 0.06; SmD2 , 4.00 +- 0.00; U1-70K , 4.04 +- 0.03; U1C , 3.92 +- 0.09; and SmE , 4.00 +- 0.00). RNAi lines were non-toxic when expressed independently (top row). See also Data S1 , tab iii. (C) Tau WT expression in the adult retina ( Rh1-GAL4 ) causes reduced electroretinogram (ERG) amplitude in 5-day-old flies, and this phenotype is enhanced in SmB MG heterozygotes (n > 10 for quantification). See also Figures S2A - S2C . (D) Pan-neuronal expression of Tau R406W ( elav-GAL4 ) causes progressive neuropil vacuolization (arrows) in hematoxylin and eosin-stained frontal brain sections in 10-day-old adult flies, and this phenotype is enhanced in SmB MG heterozygotes (n > 8